The earnings call presented a generally positive outlook with significant revenue growth, successful product launches, and strategic capital raises. However, there were challenges with gross margin decline, increased administrative expenses, and a delay in achieving EBITDA positivity. Overall, the positive aspects of growth and expansion outweigh the financial setbacks.

Company Guidance

During TriSalus Life Sciences' second quarter 2025 earnings call, the company reported strong financial performance with $11.2 million in net sales, marking a 52% increase year-over-year and a 22% sequential gain. The company highlighted the successful launch of the TriNav FLX infusion system and completion of a $22 million private placement. Gross margin for the quarter was 84%, down slightly from 88% in the previous year, attributed to lower manufacturing efficiency with new products. Operating losses decreased to $7.3 million from $8.2 million in Q2 2024, and adjusted EBITDA loss improved to $5.3 million. TriSalus reiterated its guidance for 50% revenue growth and expects to achieve cash flow positivity in early 2026. The company is advancing its TriNav product portfolio, expanding clinical applications, and focusing on partnership opportunities for nelitolimod to preserve long-term value while minimizing development expenses.

Strong Revenue Growth

TriSalus Life Sciences reported $11.2 million in net sales for Q2 2025, marking a 52% increase compared to Q2 2024 and a 22% sequential gain over Q1 2025.

Launch of TriNav FLX Infusion System

The company successfully launched the TriNav FLX infusion system, which has demonstrated improved trackability and is engineered for use in tortuous vascular anatomy.

Expansion of Product Portfolio

TriSalus expanded its product suite with the launch of TriNav LD and TriGuide for larger vessels, and the full commercial launch of TriNav FLX.

Successful Capital Raise

TriSalus completed a $22 million private placement with healthcare-focused institutional investors, strengthening its balance sheet.

Increased Unique Ordering Accounts

The number of unique ordering accounts increased by 28% year-over-year.

New Reimbursement Code for TriNav

Centers for Medicare and Medicaid Services issued code C8004, providing coverage for simulation or mapping procedures using TriNav.

Reduction in Operating Losses

Operating losses for Q2 2025 were reduced to $7.3 million from $8.2 million in Q2 2024.

TriSalus Life Sciences (TLSI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TLSI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.14 / -	-0.12	―	―	―
Aug 12, 2025	2025 (Q2)	-0.21 / -0.27	-0.21	-28.57% (-0.06)	―
May 15, 2025	2025 (Q1)	-0.22 / -0.39	-0.6	35.00% (+0.21)	―
Mar 27, 2025	2024 (Q4)	-0.32 / -0.40	-1.56	74.36% (+1.16)	―
Nov 14, 2024	2024 (Q3)	-0.35 / -0.12	-0.13	7.69% (+0.01)	―
Aug 15, 2024	2024 (Q2)	-0.46 / -0.21	-0.89	76.40% (+0.68)	―
May 15, 2024	2024 (Q1)	- / -	-0.055	―	―
Apr 01, 2024	2023 (Q4)	-0.58 / -0.60	-0.055	-990.91% (-0.54)	―
Nov 14, 2023	2023 (Q3)	- / -0.13	0.021	-719.05% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TLSI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$3.65	$3.95	+8.22%
May 15, 2025	$4.90	$5.11	+4.29%
Mar 27, 2025	$5.58	$5.50	-1.43%
Nov 14, 2024	$4.50	$4.01	-10.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does TriSalus Life Sciences (TLSI) report earnings?

TriSalus Life Sciences (TLSI) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is TriSalus Life Sciences (TLSI) earnings time?

TriSalus Life Sciences (TLSI) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TLSI EPS forecast?

TLSI EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing